ER1120 (PDF)

22/02/2017

WHO Classification:
Towards Personalized Medicine in Haematology
CityWest Hotel, Saggart (Dublin), Ireland
9-11 March, 2017
Chairs: Mario Cazzola (Pavia), Matteo G Della Porta (Milan), Torsten Haferlach (Munich),
Eva Hellstrdm-Lindberg (Stockholm), Andreas Hochhaus (Jena)

Thursday, March 9,2017
13:00-13:15 Welcome
SESSION I

Introduction to the training course
Genomics of Haematological Malignancies for the Practicing Clinician
Chair: Bob Lowenberg (Rotterdam)

13:15-13:40
13:40-13:45

ABCs of genomics Nick Cross (Salisbury)
Discussion

13:45-14:10
14:10-14:15

Genomic applications in the clinic: are we ready? Andreas Hochhaus (Jena)
Discussion

14:15-14:40
14:40-14:45

Next-generation sequencing data analysis: critical issues Torsten Haferlach (Munich)
Discussion

14:45-15:15

Round table/general discussion
The 2016 WHO Classification of Haematological Malignancies: what’s new?
Chair: Mario Cazzola (Pavia)

15:15-15:40
15:40-15:45

Update of the WHO classification of myeloid malignancies Mario Cazzola (Pavia)
Discussion

15:45-16:10
16:10-16:15

Update of the WHO classification of lymphoid malignancies Steven Swcrdlow (Pittsburgh)
Discussion

16:15-16:45

Round table/general discussion

16:45-17:15

Coffee Break

1

SESSION II

Biologically-Based Acute Myeloid Leukaemia (AML) Therapy
Chair: Torsten Haferlach (Munich)

17:15-17:40
17:40-17:45

Translational implications of the medical genomics Torsten Haferlach (Munich)
in AML
Discussion

17:45-18:10
18:10-18:15

Genotype-tailored therapy of AML Hartmut Dohncr (Ulm)
Discussion

18:15-18:40
18:40-18:45

Towards personalized medicine in AML Bob Ldwcnberg (Rotterdam)
Discussion

18:45-19:10
19:10-19:15

Precision medicine in AML: hope, hype or both? Robert P. Gale (London)
Discussion

19:15-19:30

Round table/general discussion

19:30

Poster Viewing and Get together

SESSION III

Molecular Haematology: the Paradigm of Myeloproliferative Neoplasms (MPN)
Chair: Andreas Hochhaus (Jena)

08:45-09:10
09:10-09:15

The evolving genomic landscape of Philadelphia-negative Mario Cazzola (Pavia)
classical MPN
Discussion

09:15-09:40
09:40-09:45

Genotype-based clinical decision making in MPN Francesco Passamonti (Varese)
Discussion

09:45-10:10
10:10-10:15

The future of JAK inhibition in MPN Alessandro Vannucchi (Florence)
Discussion

10:15-10:45

Round table/general discussion

10:45-11:15

Coffee Break

SESSION IV

Modern Diagnostics Applied to the Evaluation of Minimal Residual Disease:
the example of CML
Chair: Nick Cross (Salisbury)

11:15-11:40
11:40-11:45

CML monitoring: why, which, where and when? Andreas Hochhaus (Jena)
Discussion

11:45-12:10
12:10-12:15

Current status of standardization efforts for PCR in CML Nick Cross (Salisbury)
Discussion

12:15-12:40
12:40-12:45

Clinical significance of NGS in second-line Simona Soverini (Bologna)
treatment and beyond
Discussion

12:45-13:15

Round table/general discussion
2

13:15-14:15

SESSION V

Lunch

Changing Paradigms in Acute Lymphocytic Leukaemia (ALL):
from the genome to the patient
Chair: Jacob Rowe (Jerusalem)

14:15-14:40
14:40-14:45

The genomic landscape of ALL Christine Harrison (Newcastle)
Discussion

14:45-15:10
15:10-15:15

Targeting signaling pathways in ALL: new insights Charles Mullighan (Memphis)
Discussion

15:15-15:40
15:40-15:45

Clinically defining and managing high-risk adult patients Jacob Rowe (Jerusalem)
with ALL
Discussion

15:45-16:15

Round table/general discussion

16:15-16:45

Coffee Break

SESSION VI

16:45-17:10
17:10-17:15

The Dawn of the Molecular Era in Myelodysplastic Syndromes (MDS) and
Myclodysplastic/Mycloprolifcrative Neoplasms (MDS/MPN)
Chair: Eva llcllstrom-Lindbcrg (Stockholm)
Integration of somatic mutations into classification and Luca Malcovati (Pavia)
prognostic scores in MDS
Discussion

17:40-17:45

Implications of patient genome on clinical decision making Michaela Fontenay (Paris)
in MDS/MPN
Discussion

17:45-18:10
18:10-18:15

Personalized transplantation procedures in myeloid malignancies Matteo Della Porta (Milan)
Discussion

18:15-18:40

Treating anaemia according to patient genome Eva Hellstrom-Lindberg

18:40-18:45

Discussion

18:45-19:15

Round table/general discussion

20.00

Dinner

17:15-17:40

(Stockholm)

Saturday, March 11,2017
08:45-09:45

Meet the Expert sessions
"Choosing Wisely" - Distinction between Clinically Relevant Genomic Information which is
Crucial for Decision Making vs. Academic Interest
MPN - Andreas Hochhaus (Jena)
AML - Robert P. Gale (London)
MDS - Matteo Della Porta (Milan)
CLL - Gianluca Gaidano (Novara)

3

SESSION VII

Personalized Treatment Strategies in Lymphoprolifcrative Disorders
Chair: Gianluca Gaidano (Novara)

09:45-10:10

Therapeutic targeting of biology in CLL: focus on signaling kinase
Stephan Stilgenbauer (Ulm)
and apoptosis modulation
Discussion

10:10-10:15
10:15-10:40

Gianluca Gaidano (Novara)

10:40-10:45

Mutations in CLL and how they
affect therapy choice (focus on NOTCH 1, SF3B1, and TP53)
Discussion

10:45-11:10
11:10-11:15

Genomic stratification for the treatment of lymphomas
Discussion

Laura Pasqualucci (New York)

11:15-11:40
11:40-11:45

Hairy cell leukaemia: targeting mutant BRAF
Discussion

Brunangelo Falini (Perugia)

11:45-12:15

Round lable/general discussion

12:15-12:30

Closing Remarks

MEETING CLOSURE

4